Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05119686 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
A Phase 2 study, sponsored by Arthrosi Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT05119686: Completed Phase 2 study, sponsored by Arthrosi Therapeutics.
NCT05119686 is a Phase 2 study that has completed, run by Arthrosi Therapeutics. The registered enrollment target is 140 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05119686, a Phase 2 study, has completed, sponsored by Arthrosi Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.
Primary Outcome
Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level \< 6 mg/dL following 6 weeks of dosing
Interventions
- DRUG Placebo
- DRUG AR882 Dose 1
- DRUG AR882 Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 2 |
What the finished NCT05119686 record still lists
NCT05119686 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05119686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05119686 about?
NCT05119686 is a clinical study titled "Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients". This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.
What is the current status of trial NCT05119686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2021-11-16. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT05119686?
The interventions under investigation include: Placebo (DRUG), AR882 Dose 1 (DRUG), AR882 Dose 2 (DRUG).
Who is sponsoring clinical trial NCT05119686?
This trial is sponsored by Arthrosi Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05119686's enrollment target sits among peer trials
140 512th of 2000 higher than 1,476 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI